CXCR3 and neoplasm: Because IL-15SA/IL-15RαSu-Fc significantly induces the expansion of high effector NK cells (Figure 4), which have been shown to express a high level of CXCR3 [21, 22] and exhibit superior migratory capacity [21, 22], incorporating IL-15SA/IL-15RαSu-Fc into a vaccine-based immunotherapy may synergistically enhance priming and activation of tumor-antigen specific T cells, mediated by this subpopulation of NK cells.